$Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report$

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report

Yuanyang Zhao,1,* Yuxing Chen,1,* Huaying Huang,1 Xi Li,2 Lin Shao,2 Hao Ding1 1Department of Respiratory Disease, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 212002, People’s Republic of China; 2Department of Medicine, Burning Rock Biotech, Guangzhou, 510300,...

Full description

Bibliographic Details
Main Authors:	Zhao Y, Chen Y, Huang H, Li X, Shao L, Ding H
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-05-01
Series:	OncoTargets and Therapy
Subjects:	nsclc egfr-mutant tki afatinib apatinib
Online Access:	https://www.dovepress.com/significant-benefits-of-afatinib-and-apatinib-in-a-refractory-advanced-peer-reviewed-fulltext-article-OTT

Similar Items

The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo
by: Mingtao Liu, et al.
Published: (2019-10-01)

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
by: E. A. van de Stadt, et al.
Published: (2020-08-01)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
by: Xue Yang, et al.
Published: (2021-05-01)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
by: Jing Liu, et al.
Published: (2019-07-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Wan-Ling Tan, et al.
Published: (2018-12-01)

Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: Results from a real‐world study in South Korea
by: Taeyun Kim, et al.
Published: (2021-09-01)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018-10-01)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
by: Chiao-En Wu, et al.
Published: (2021-07-01)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by: Silvia La Monica, et al.
Published: (2017-12-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways
by: Zhen Liu, et al.
Published: (2021-02-01)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
by: Nahomi Tokudome, et al.
Published: (2020-02-01)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
by: Junyan Tao, et al.
Published: (2020-09-01)

TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS
by: T. Y. SEMIGLAZOVA, et al.
Published: (2016-12-01)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
by: Nobuaki Kobayashi, et al.
Published: (2020-08-01)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
by: Sabine Zöchbauer-Müller, et al.
Published: (2021-01-01)

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
by: Azuma, K., et al.
Published: (2022)

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
by: Yozo Sato, et al.
Published: (2021-01-01)

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
by: Lu S
Published: (2019-02-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
by: Lin L, et al.
Published: (2020-09-01)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
by: Wu YL, et al.
Published: (2018-11-01)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
by: Yang Wei, MD, et al.
Published: (2021-07-01)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
by: Keunchil Park, et al.
Published: (2021-07-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer Cells
by: Chia-Chi Hsu, et al.
Published: (2021-01-01)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
by: Daisuke Hayakawa, et al.
Published: (2020-01-01)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
by: Alex Friedlaender, et al.
Published: (2021-03-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction
by: Rui Han, et al.
Published: (2020-06-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)